RND Pharmaceuticals Inc.
- Biotech or pharma, therapeutic R&D
- Diagnostics
RND is a New York-based company and has two objectives:
- The development of a novel and proprietary test (RND-101) for the prediction of resistance to Immune Checkpoint Inhibitors (ICI). Initial PoC has been demonstrated.
- The development of Therapeutics to overcome resistance to ICI
This tumor-tissue biopsy-based test is intended to be used for patient selection by Oncologists to select the right patients for ICI therapy.
In addition, this predictive test could be used to enrich for potential responders, and hence reduce trial sample size, cost and risk with Clinical Trials using ICI.
In the future, we aim to develop Therapeutics to overcome resistance to ICI therapy, guided by this test.
We welcome the opportunity to discuss a potential collaboration with you.
Address
New YorkNew York
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}